DRUG · Unmapped registry intervention
TY-9591
Find medicine records ·
Find other trials using this name
Clinical trial
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
NCT05948813
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Osimertinib
Normalized identity: osimertinibView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
NSCLCverified · MONDO: non-small cell lung carcinoma
EGFR Activating Mutationunresolved
Brain Metastasesunresolved
Interventions
TY-9591DRUG
OsimertinibDRUG · verified · RxNorm: osimertinib
Sponsors & collaborators
TYK Medicines, Inclead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05948813 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.